Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy

A 56-year-old man with multiple cardiac manifestations of type 1 myotonic dystrophy, including severe, nonischemic cardiomyopathy, presented in refractory cardiogenic shock requiring inotropic therapy. Given his wishes to die without having any intravenous medications, he was started on oral probene...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Evan C., Rubinstein, Jack, Strande, Jennifer L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301499/
https://www.ncbi.nlm.nih.gov/pubmed/34316787
http://dx.doi.org/10.1016/j.jaccas.2019.07.008
Descripción
Sumario:A 56-year-old man with multiple cardiac manifestations of type 1 myotonic dystrophy, including severe, nonischemic cardiomyopathy, presented in refractory cardiogenic shock requiring inotropic therapy. Given his wishes to die without having any intravenous medications, he was started on oral probenecid therapy, which allowed for successful elimination of his intravenous therapies. (Level of Difficulty: Intermediate.)

Ejemplares similares